title: Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery.
abstract: Inflammatory breast cancer (IBC) is rare and associated with a poor prognosis. Following neoadjuvant chemotherapy or endocrine therapy, the multidisciplinary team selected a small number of patients for breast-conservation therapy (BCT). The aim of this study was to determine the outcome of IBC patients treated with BCT in Edinburgh.
  
  
  
  Between January 1999 and December 2013, thirty-five women with IBC were treated by BCT. The median follow-up was 80 months.
  
  
  
  The 5-year actuarial survival for the 35 patients was 70.3 %. Median survival for 20 neoadjuvant chemotherapy patients was 12.9 years (95 % CI 7.6, 18.1), and for 14 patient neoadjuvant endocrine therapy patients, it was 11.8 years (95 % CI 1.1, 22.6) (p = 0.34). Five patients developed locoregional recurrence (LRR) between 11 and 72 months after BCT (median 37 months). Three had breast only recurrence, one patient had both breast and axillary recurrence, and one developed axillary recurrence. The 5-year LR-free survival was 87.5 % (95 % CI 76.0, 99.0). In 4 of the 5 patients with LRR, systemic metastases were diagnosed within 6 months and survival post-LRR in these 4 patients was short.
  
  
  
  IBC is not an absolute contraindication to BCT. LRR in patients after BCT appears part of widespread recurrent disease rather than inadequate local treatment. Multicentre data should be collected to confirm that women with IBC who have a good response to systemic therapy may be offered BCT in the knowledge that in a larger series our observations are confirmed.
authors.affiliation: Edinburgh Breast Unit, NHS Lothian, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK.
authors.forename: Monika
authors.initials: M
authors.lastname: Brzezinska
authors.affiliation: Centre for Population Health Sciences, University of Edinburgh Medical School, Edinburgh, UK.
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Williams
authors.affiliation: Department of Pathology, Western General Hospital, Edinburgh, UK.
authors.forename: Jeremy
authors.initials: J
authors.lastname: Thomas
authors.affiliation: Edinburgh Breast Unit, NHS Lothian, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, UK. mike.dixon@ed.ac.uk.|Breast Cancer Now Research Unit, Western General Hospital, Edinburgh, UK. mike.dixon@ed.ac.uk.
authors.forename: J
authors.initials: J
authors.lastname: Michael Dixon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D015412:Mastectomy, Segmental / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D016019:Survival Analysis; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor
keywords: BCT; Breast-conserving therapy; Edinburgh Breast Unit; IBC; IBC for BCT; Inflammatory breast cancer; Treatment outcomes